Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Natera (NASDAQ: NTRA), a leading cell-free DNA testing company, has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team will deliver a presentation and conduct a Q&A session with investors on Wednesday, January 15, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
Interested parties can access a live webcast of the event through the investor relations section of Natera's website at investor.natera.com. A recording of the presentation will be made available shortly after the conference concludes.
Natera (NASDAQ: NTRA), un'azienda leader nel settore dei test del DNA libero da cellule, ha annunciato la sua partecipazione al prossimo 43° Annuale J.P. Morgan Healthcare Conference di San Francisco. Il team di gestione dell'azienda presenterà e condurrà una sessione di domande e risposte con gli investitori mercoledì 15 gennaio 2025, alle 9:00 PT (12:00 ET).
Le parti interessate possono accedere a una diretta streaming dell'evento attraverso la sezione delle relazioni con gli investitori sul sito web di Natera all'indirizzo investor.natera.com. Una registrazione della presentazione sarà resa disponibile poco dopo la conclusione della conferenza.
Natera (NASDAQ: NTRA), una empresa líder en pruebas de ADN libre de células, ha anunciado su participación en la próxima 43ª Conferencia Anual de Atención Médica de J.P. Morgan en San Francisco. El equipo de gestión de la empresa hará una presentación y llevará a cabo una sesión de preguntas y respuestas con los inversores el miércoles 15 de enero de 2025, a las 9:00 a.m. PT (12:00 p.m. ET).
Las partes interesadas pueden acceder a una transmisión en vivo del evento a través de la sección de relaciones con inversores del sitio web de Natera en investor.natera.com. Se estará disponible una grabación de la presentación poco después de que concluya la conferencia.
네이타라 (NASDAQ: NTRA), 세포 유리 DNA 검사 분야의 선두주자가 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 1월 15일 수요일 오전 9시 PT (오후 12시 ET)에 투자자들과의 프레젠테이션 및 Q&A 세션을 진행할 것입니다.
관심 있는 분들은 네이타라 웹사이트의 투자자 관계 섹션을 통해 이벤트의 실시간 웹캐스트에 접근할 수 있습니다. 프레젠테이션의 녹화본은 컨퍼런스 종료 직후에 제공될 예정입니다.
Natera (NASDAQ: NTRA), une entreprise leader dans le domaine des tests d'ADN libre de cellules, a annoncé sa participation à la prochaine 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco. L'équipe de direction de l'entreprise fera une présentation et animera une session de questions-réponses avec les investisseurs le mercredi 15 janvier 2025, à 9h00 PT (12h00 ET).
Les parties intéressées peuvent accéder à un webinaire en direct de l'événement via la section des relations avec les investisseurs sur le site de Natera à l'adresse investor.natera.com. Un enregistrement de la présentation sera disponible peu après la fin de la conférence.
Natera (NASDAQ: NTRA), ein führendes Unternehmen im Bereich der zellfreien DNA-Tests, hat seine Teilnahme an der bevorstehenden 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco angekündigt. Das Management-Team des Unternehmens wird am Mittwoch, den 15. Januar 2025, um 9:00 Uhr PT (12:00 Uhr ET) eine Präsentation halten und eine Fragen-und-Antworten-Runde mit Investoren durchführen.
Interessierte Parteien können über den Bereich Investor Relations auf der Website von Natera unter investor.natera.com auf einen Live-Stream des Events zugreifen. Eine Aufnahme der Präsentation wird kurz nach dem Ende der Konferenz verfügbar sein.
- None.
- None.
A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107036377/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
When is Natera (NTRA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Natera's (NTRA) J.P. Morgan Healthcare Conference presentation?
What will be included in Natera's (NTRA) J.P. Morgan Healthcare Conference session?
Will there be a replay available of Natera's (NTRA) J.P. Morgan Healthcare Conference presentation?
